GlassScriptPhysician profile
John M Facciani
NPI 1417951989
$3,200.45
in general payments reported to CMS, 2019-2025
9 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $19.40 · 2022: $116 · 2023: $300 · 2024: $2,533 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679 · Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
| Food and Beverage | $284.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,678.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished) |
| Bausch & Lomb Americas INC. | $116.13 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $113.95 | 2025 | Eylea Hd |
| Allergan, INC. | $101.10 | 2019 | |
| Horizon Therapeutics Plc | $99.88 | 2023 | Tepezza |
| Abbvie INC. | $55.23 | 2023-2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $15.43 | 2025 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Facciani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.